Nikon Eclipse E800 at 10× magnification and analyzed using an imaging software-ImageJ. The difference between the muscle cross-sectional areas of the left hind limbs (ischemic limbs) between these groups was found to be significant (leupeptin group: 774.57 µm 2 versus 472.70 µm 2 for the control; P = 0.043). These 2 values were significantly lower as compared to their respective right muscle fascicle areas (where no tourniquet was applied; 1,725.30 µm 2 and 1,548.22 µm 2 for the leupeptin and control groups, respectively). However, the differences in the sciatic functional index scores between these 2 groups were not found to be different (P = 0.785).
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PURPOSE: Radiotherapy is an important curative and preventative oncologic treatment but causes significant collateral damage to healthy soft tissue in the radiation field. The longterm outcome of radiotherapy is pathologic tissue fibrosis, which distorts tissue esthetic appearance, impairs function, and can profoundly effect patient quality of life. Fat grafting is gaining popularity as a technique able to restore and regenerate irradiated tissue. Grafted fat, however, is often poorly retained in the damaged and hypovascular recipient site. We have previously shown that preconditioning the irradiated tissue with subcutaneous injections of deferoxamine (DFO) can improve perfusion and subsequent fat graft retention. Repeated subcutaneous injections, however, may be painful and further irritate the recipient site. In this study, we therefore explored whether DFO preconditioning using a transdermal drug delivery system (TDDS) could reverse radiation-induced soft tissue damage and enhance subsequent fat graft survival.
METHODS:
Female CD-1 nude mice underwent external beam irradiation of the scalp with 30 Gy fractionated in 5 Gy doses every 2 days for a total of 12 days. After a 5-week recovery period, mice either received a DFO-TDDS or a control carrier TDDS, which was replaced changed every other day for a 2-week period. Laser Doppler analysis was recorded before irradiation, following irradiation, and 24 hours following each TDDS treatment. Human lipoaspirate was then injected into the subcutaneous plane of the scalp (200 μl/graft), and fat graft retention was monitored radiographically every 2 weeks for 8 weeks total, at which point the skin and transplanted fat were harvested for mechanical strength testing and histologic analysis. Blood samples were obtained from mice receiving the DFO-TDDS after 24 hours to assess systemic levels of DFO by mass spectrometry.
RESULTS:
The DFO-TDDS application resulted in significantly increased perfusion at the recipient site, as indicated by both laser Doppler analysis and CD31 immunofluorescent staining. The mice receiving DFO treated also had reduced skin stiffness, and significantly greater fat retention compared to the mice receiving the control carrier TDDS. Intravenous systemic levels of DFO were below a quantifiable level at 24 hours after DFO-TDDS placement.
CONCLUSIONS:
Transdermal DFO delivery offers an effective and noninvasive mechanism to improve perfusion and reduce stiffness of irradiated tissue. These findings are also associated with improved fat graft retention at irradiated, DFOpreconditioned recipient sites making this approach promising in the reconstruction of postoncologic irradiated soft tissue defects.
